ReviewJapanese journal of radiology2026
Imaging of benign salivary gland tumors under the fifth WHO classification, with a focus on rare histologic types and newly listed entities-Part II.
Review in Japanese journal of radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The World Health Organization (WHO) Classification of Head and Neck Tumors was updated from the fourth edition (published in 2017) to the fifth edition (published in 2024). The current WHO classification lists 15 benign and 21 malignant epithelial salivary gland tumors (SGTs). Among the benign epithelial tumors, four entities are newly listed: intercalated duct adenoma/hyperplasia, striated duct adenoma, sclerosing polycystic adenoma, and keratocystoma. This second article in a two-part review series summarizes the four newly listed benign SGTs, focusing on their classification background, clinicopathologic features, and reported imaging findings. As the published imaging literature remains limited, radiologic-pathologic correlation remains essential for recognizing these rare entities and avoiding overinterpretation of benign lesions. The aims of this review are to clarify the currently recognized imaging features of these rare tumors while emphasizing the need for careful integration of imaging, histopathologic, immunohistochemical, and molecular findings.
Indexed as
Identifiers
42484837What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.